Can a simple test spot heart damage in cancer survivors?
NCT ID NCT05201014
First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study looks at whether a special ECG and a blood test can find early signs of heart weakness in adult cancer survivors who had certain chemotherapy. Researchers will check how well these tests work compared to standard heart imaging. The goal is to gather information needed to create a national screening program for long-term heart monitoring.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, cost-effective screening program to catch heart problems early in cancer survivors.
- What could go wrong
- This is a small pilot study, so results may not apply to all survivors. The tests might not be accurate enough for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
112 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
200 cancer survivors who are 1 year out from anthracycline-based therapy.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥18 years of age prior to enrollment and anthracycline start date * Diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year after completion of anthracycline therapy, including patients from 6-12 months and greater than 1 year post-anthracycline exposure. * Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same Exclusion Criteria: * LVEF \<50% or prior confirmed history of cardiomyopathy, heart failure, left bundle branch block, or paced rhythm * Patients with a history of persistent atrial fibrillation (afib) that are not in afib remission. Include if the most recent ECG does not show afib. Atrial flutter treated the same. * Individuals with pacemakers, defibrillators, or other implanted electronic devices * Inability/unwillingness of individual to give written informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- Can colorectal surgery patients go home in two days?
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a nurse and a neighbor help tame chronic disease?